Current trends in initial management of hypopharyngeal cancer: The declining use of open surgery

Head and Neck

Volumn 34, Issue 2, 2012, Pages 270-281

  Takes, Robert P ^a   Strojan, Primož ^b   Silver, Carl E ^c   Bradley, Patrick J ^d   Haigentz, Missak ^c   Wolf, Gregory T ^e   Shaha, Ashok R ^f   Hartl, Dana M ^g,h   Olofsson, Jan ⁱ   Langendijk, Johannes A ^j   Rinaldo, Alessandra ^k   Ferlito, Alfio ^k  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h UNIVERSITÉ SORBONNE NOUVELLE PARIS 3   (France)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k UNIVERSITY OF UDINE   (Italy)

more..

Author keywords

chemoradiotherapy; hypopharynx; laryngopharyngectomy; squamous cell carcinoma; treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; TAXANE DERIVATIVE;

ASPIRATION PNEUMONIA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CERVICAL FIBROSIS; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DYSPHAGIA; EAR NOSE THROAT SURGERY; FIBROSIS; FUNCTIONAL ASSESSMENT; HUMAN; HYPOPHARYNGECTOMY; HYPOPHARYNX CANCER; INTENSITY MODULATED RADIATION THERAPY; LARYNGECTOMY; LASER SURGERY; LYMPHEDEMA; META ANALYSIS (TOPIC); MINIMALLY INVASIVE SURGERY; MORBIDITY; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; OTOTOXICITY; OVERALL SURVIVAL; PARTIAL PHARYNGECTOMY; PHARYNX RECONSTRUCTION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROBOTIC SURGERY; ROBOTICS; SALVAGE THERAPY; SKIN TOXICITY; SURGICAL APPROACH; SURVIVAL RATE; THROAT SURGERY; TOTAL LARYNGECTOMY; TOTAL LARYNGOPHARYNGECTOMY; TRANSORAL LASER SURGERY; TREATMENT OUTCOME; TREND STUDY; XEROSTOMIA;

EID: 84855704060     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21613     Document Type: Review

References (101)

1. Hall SF, Groome PA, Irish J, O'Sullivan B,. The natural history of patients with squamous cell carcinoma of the hypopharynx. Laryngoscope 2008; 118: 1362-1371.
2. Cooper JS, Porter K, Mallin K, et al. National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 2009; 31: 748-758.
3. Pingree TF, Davis RK, Reichman O, Derrick L,. Treatment of hypopharyngeal carcinoma: a 10-year review of 1,362 cases. Laryngoscope 1987; 97: 901-904. (Pubitemid 18022595)
4. Kraus DH, Zelefsky MJ, Brock HA, Huo J, Harrison LB, Shah JP,. Combined surgery and radiation therapy for squamous cell carcinoma of the hypopharynx. Otolaryngol Head Neck Surg 1997; 116: 637-641. (Pubitemid 27355236)
5. Eckel HE, Staar S, Volling P, Sittel C, Damm M, Jungehuelsing M,. Surgical treatment for hypopharynx carcinoma: feasibility, mortality, and results. Otolaryngol Head Neck Surg 2001; 124: 561-569. (Pubitemid 33733773)
6. Sewnaik A, Hoorweg JJ, Knegt PP, Wieringa MH, van der Beek JM, Kerrebijn JD,. Treatment of hypopharyngeal carcinoma: analysis of nationwide study in the Netherlands over a 10-year period. Clin Otolaryngol 2005; 30: 52-57. (Pubitemid 40529468)
7. Gupta T, Chopra S, Agarwal JP, et al. Squamous cell carcinoma of the hypopharynx: single-institution outcome analysis of a large cohort of patients treated with primary non-surgical approaches. Acta Oncol 2009; 48: 541-548.
8. Gourin CG, Terris DJ,. Carcinoma of the hypopharynx. Surg Oncol Clin N Am 2004; 13: 81-98. (Pubitemid 38328495)
9. Buckley JG, MacLennan K,. Cervical node metastases in laryngeal and hypopharyngeal cancer: a prospective analysis of prevalence and distribution. Head Neck 2000; 22: 380-385. (Pubitemid 30413304)
10. Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V, Shedd DP,. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 1987; 154: 439-442. (Pubitemid 18024393)
11. Kim S, Wu HG, Heo DS, Kim KH, Sung MW, Park CI,. Advanced hypopharyngeal carcinoma treatment results according to treatment modalities. Head Neck 2001; 23: 713-717. (Pubitemid 32751486)
12. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T,. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890-899. (Pubitemid 26230640)
13. Chen SW, Tsai MH, Yang SN, Liang JA, Shiau AC, Lin FJ,. Hypopharyngeal cancer treatment based on definitive radiotherapy: who is suitable for laryngeal preservation? J Laryngol Otol 2008; 122: 506-512.
14. Tsou YA, Hua JH, Lin MH, Tsai MH,. Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer-does tumor volume correlate with central necrosis and tumor pathology? ORL J Otorhinolaryngol Relat Spec 2006; 68: 206-212.
15. Lefebvre JL, Ang KK,; Larynx Preservation Consensus Panel. Larynx preservation clinical trial design: key issues and recommendations - a consensus panel summary. Head Neck 2009; 31: 429-441.
16. Ferlito A, Medina JE, Silver CE, Rinaldo A, Paleri V,. Elective neck dissection for squamous carcinoma of the head and neck. In:, Ferlito A, Robbins KT, Silver CE, editors. Neck dissection-Management of regional disease in head and neck cancer. San Diego: Plural Publishing Company; 2010. p 179-192.
17. Joo YH, Sun DI, Cho KJ, Cho JH, Kim MS,. The impact of paratracheal lymph node metastasis in squamous cell carcinoma of the hypopharynx. Eur Arch Otorhinolaryngol 2010; 267: 945-950.
18. Wiegand S, Esters J, Müller HH, et al. Is it necessary to dissect levels I and IIB in hypopharyngeal cancer? Acta Otolaryngol 2010; 130: 747-752.
19. Ozer E, Karapinar U, Ryoo C, Agrawal A, Schuller DE,. When to address level I lymph nodes in neck dissections? Otolaryngol Head Neck Surg 2010; 142: 355-358.
20. Kim YH, Koo BS, Lim YC, Lee JS, Kim SH, Choi EC,. Lymphatic metastases to level IIb in hypopharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132: 1060-1064.
21. Frank JL, Garb JL, Kay S, et al. Postoperative radiotherapy improves survival in squamous cell carcinoma of the hypopharynx. Am J Surg 1994; 168: 476-480. (Pubitemid 24345703)
22. Bova R, Goh R, Poulson M, Coman WB,. Total pharyngolaryngectomy for squamous cell carcinoma of the hypopharynx: a review. Laryngoscope 2005; 115: 864-869. (Pubitemid 40604695)
23. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005; 27: 843-850. (Pubitemid 41395696)
24. Richmon JD, Samji HA, Deschler DG,. National laryngopharyngectomy and reconstructive surgery survey. Laryngoscope 2009; 119: 1472-1478.
25. Cusumano R, Silver C, Brauer R, Strauch B,. Pectoralis myocutaneous flap for replacement of cervical esophagus. Head Neck 1989; 11: 450-456. (Pubitemid 19210527)
26. Lam K, Wei V, Lau V,. Avoiding stenosis in the tubed greater pectoral flap in pharyngeal repair. Arch Otolaryngol Head Neck Surg 1987; 113: 428-431. (Pubitemid 17056469)
27. Richmon JD, Brumund KT,. Reconstruction of the hypopharynx: current trends. Curr Opin Otolaryngol Head Neck Surg 2007; 15: 208-212. (Pubitemid 47056614)
28. Robb GL, Lewin JS, Deschler DG, et al. Speech and swallowing outcomes in reconstructions of the pharynx and cervical esophagus. Head Neck 2003; 25: 232-244. (Pubitemid 36245883)
29. Clark JR, Gilbert R, Irish J, Brown D, Neligan P, Gullane PJ,. Morbidity after flap reconstruction of hypopharyngeal defects. Laryngoscope 2006; 116: 173-181. (Pubitemid 44383919)
30. Ogura JH, Marks JE, Freeman RB,. Results of conservation surgery for cancers of the supraglottis and pyriform sinus. Laryngoscope 1980; 90: 591-600. (Pubitemid 10131490)
31. Laccourreye O, Mérite-Drancy A, Brasnu D, et al. Supracricoid hemilaryngopharyngectomy in selected pyriform sinus carcinoma staged as T2. Laryngoscope 1993; 103: 1373-1379. (Pubitemid 23354195)
32. Laccourreye O, Ishoo E, de Mones E, Garcia D, Kania R, Hans S,. Supracricoid hemilaryngopharyngectomy in patients with invasive squamous cell carcinoma of the pyriform sinus. Part I: Technique, complications, and long-term functional outcome. Ann Otol Rhinol Laryngol 2005; 114: 25-34. (Pubitemid 40116511)
33. Kania R, Hans S, Garcia D, Brasnu D, De Mones E, Laccourreye O,. Supracricoid hemilaryngopharyngectomy in patients with invasive squamous cell carcinoma of the pyriform sinus. Part II: Incidence and consequences of local recurrence Ann Otol Rhinol Laryngol 2005; 114: 95-104.
34. Chevalier D, Watelet JB, Darras JA, Piquet JJ,. Supraglottic hemilaryngopharyngectomy plus radiation for the treatment of early lateral margin and pyriform sinus carcinoma. Head Neck 1997; 19: 1-5. (Pubitemid 26425082)
35. Makeieff M, Mercante G, Jouzdani E, Garrel R, Crampette L, Guerrier B,. Supraglottic hemipharyngolaryngectomy for the treatment of T1 and T2 carcinomas of laryngeal margin and piriform sinus. Head Neck 2004; 26: 701-705. (Pubitemid 39014635)
36. Plouin-Gaudon I, Lengelé B, Desuter G, et al. Conservation laryngeal surgery for selected pyriform sinus cancer. Eur J Surg Oncol 2004; 30: 1123-1130. (Pubitemid 40267820)
37. Strong MS, Jako GJ,. Laser surgery in the larynx. Early clinical experience with continuous CO2 laser. Ann Otol 1972; 81: 791-798.
38. Vaughan CW,. Transoral laryngeal surgery using the CO2 laser: laboratory experiments and clinical experience. Laryngoscope 1978; 88: 1399-1420.
39. Zeitels SM, Koufman JA, Davis RK, Vaughan CW,. Endoscopic treatment of supraglottic and hypopharynx cancer. Laryngoscope 1994; 104: 71-78. (Pubitemid 24028038)
40. Steiner W,. Therapy of hypopharyngeal cancer. Part III: The concept of minimally invasive therapy of cancers of the upper aerodigestive tract with special reference to hypopharyngeal cancer and trans-oral laser microsurgery. HNO 1994; 42: 104-112. (in German). (Pubitemid 24087600)
41. Steiner W, Ambrosch P, Hess CF, Kron M,. Organ preservation by transoral laser microsurgery in piriform sinus carcinoma. Otolaryngol Head Neck Surg 2001; 124: 58-67. (Pubitemid 32096782)
42. Rudert HH, Höft S,. Transoral carbon-dioxide laser resection of hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol 2003; 260: 198-206. (Pubitemid 36583791)
43. Vilaseca I, Blanch JL, Bernal-Sprekelsen M, Moragas M,. CO2 laser surgery: a larynx preservation alternative for selected hypopharyngeal carcinomas. Head Neck 2004; 26: 953-959. (Pubitemid 39488122)
44. Kutter J, Lang F, Monnier P, Pasche P,. Transoral laser surgery for pharyngeal and pharyngolaryngeal carcinomas. Arch Otolaryngol Head Neck Surg 2007; 133: 139-144. (Pubitemid 46294114)
45. Martin A, Jäckel MC, Christiansen H, Mahmoodzada M, Kron M, Steiner W,. Organ preserving transoral laser microsurgery for cancer of the hypopharynx. Laryngoscope 2008; 118: 398-402. (Pubitemid 351640616)
46. Park YM, Lee WJ, Lee JG, et al. Transoral robotic surgery (TORS) in laryngeal and hypopharyngeal cancer. J Laparoendosc Adv Surg Tech A 2009; 19: 361-368.
47. Genden EM, Desai S, Sung CK,. Transoral robotic surgery for the management of head and neck cancer: a preliminary experience. Head Neck 2009; 31: 283-289.
48. Boudreaux BA, Rosenthal EL, Magnuson JS, et al. Robot-assisted surgery for upper aerodigestive tract neoplasms. Arch Otolaryngol Head Neck Surg 2009; 135: 397-401.
49. Godballe C, Jørgensen K, Hansen O, Bastholt L,. Hypopharyngeal cancer: results of treatment based on radiation therapy and salvage surgery. Laryngoscope 2002; 112: 834-838. (Pubitemid 34477612)
50. Foote RL,. Radiotherapy alone for early-stage squamous cell carcinoma of the larynx and hypopharynx. Int J Radiat Oncol Biol Phys 2007; 69: S31-S36. (Pubitemid 47369384)
51. Yoshimura RI, Kagami Y, Ito Y, et al. Outcomes in patients with early-stage hypopharyngeal cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2010; 77: 1017-1023.
52. Nakamura K, Shioyama Y, Kawashima M, et al. Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65: 1045-1050.
53. Rabbani A, Amdur R, Mancuso A, et al. Definitive radiotherapy for T1-T2 squamous cell carcinoma of pyriform sinus. Int J Radiat Oncol Biol Phys 2008; 72: 351-355.
54. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-1690.
55. Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009; 101: 142-152.
56. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098. (Pubitemid 37464533)
57. Forastiere A, Maor M, Weber R, et al. Long-term results of Intergroup RTOG 91-11 phase III trial to preserve the larynx-induction cisplatin/5FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proc Am Soc Clin Oncol 2006; 24:abstr 5517.
58. Weber RS, Berkey BA, Forastiere A, et al. Outcome of salvage total laryngectomy following organ preservation therapy. The Radiation Therapy Oncology Group Trial 91-11. Arch Otolaryngol Head Neck Surg 2003; 129: 44-49. (Pubitemid 36074941)
59. Olsen KD,. Reexamining the treatment of advanced laryngeal cancer. Head Neck 2010; 32: 1-7.
60. Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer 2005; 93: 279-286. (Pubitemid 43080029)
61. Pignon JP, Bourhis J, Domenge C, Designé L,. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-955. (Pubitemid 30148259)
62. Pignon JP, le Matre A, Maillard E, Bourhis J,; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
63. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101: 498-506.
64. Posner MR, Norris CM, Wirth LJ, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol 2009; 20: 921-927.
65. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86: 265-272. (Pubitemid 24057404)
66. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
67. Forastiere AA,. Larynx preservation and survival trends: should there be concern? Head Neck 2010; 32: 14-17.
68. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006; 116: 1-13. (Pubitemid 44337830)
69. Forastiere AA, Trotti AM,. Searching for less toxic larynx preservation: a need for common definitions and metrics. J Natl Cancer Inst 2009; 101: 129-131.
70. Rades D, Fehlauer F, Sheikh-Sarraf M, et al. Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer. Head Neck 2008; 30: 235-241. (Pubitemid 351251708)
71. Zuur CL, Simis YJ, Lansdaal PE, et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys 2007; 68: 1320-1325. (Pubitemid 47176789)
72. Lee WT, Akst LM, Adelstein DJ, et al. Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation. Head Neck 2006; 28: 808-812. (Pubitemid 44320534)
73. Staton J, Robbins KT, Newman L, Samant S, Sebelik M, Vieira F,. Factors predictive of poor functional outcome after chemoradiation for advanced laryngeal cancer. Otolaryngol Head Neck Surg 2002; 127: 43-47. (Pubitemid 41115026)
74. Franzmann EJ, Lundy DS, Abitbol AA, Goodwin WJ,. Complete hypopharyngeal obstruction by mucosal adhesions: a complication of intensive chemoradiation for advanced head and neck cancer. Head Neck 2006; 28: 663-670. (Pubitemid 44116890)
75. Rosenthal DI, Lewin JS, Eisbruch A,. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 2006; 24: 2636-2643. (Pubitemid 46622085)
76. Gluck I, Feng FY, Lyden T, et al. Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010; 77: 727-33
77. Hillman RE, Walsh MJ, Wolf GT, Fisher SG, Hong WK,. Functional outcomes following treatment for advanced laryngeal cancer. Part I-voice preservation in advanced laryngeal cancer. Part II-laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group. Ann Otol Rinol Laryngol Suppl 1998; 172: 1-27.
78. Terrell JE, Fisher SG, Wolf GT,. Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg 1998; 124: 964-971. (Pubitemid 28411497)
79. Fung K, Lyden TH, Lee J, et al. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. Int J Radiat Oncol Biol Phys 2005; 63: 1395-1399. (Pubitemid 41628034)
80. Caglar HB, Tishler RB, Othus M, et al. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 1110-1118.
81. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2007; 68: 1289-1298. (Pubitemid 47176817)
82. Vergeer MR, Doornaert PA, Rietveld DH, Leemans CR, Slotman BJ, Langendijk JA,. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 2009; 74: 1-8.
83. Eisbruch A, Ship JA, Dawson LA, et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg 2003; 27: 832-837. (Pubitemid 37022398)
84. Marur S, Forastiere AA,. Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer. Curr Opin Oncol 2010; 22: 206-211.
85. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
86. El-Deiry M, Funk GF, Nalwa S, et al. Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer. Arch Otolaryngol Head Neck Surg 2005; 131: 879-885. (Pubitemid 41464479)
87. Terrell JE, Ronis DL, Fowler KE, et al. Clinical predictors of quality of life in head and neck cancer patients. Arch Otolaryngol Head Neck Surg 2004; 130: 401-408. (Pubitemid 38456313)
88. Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998; 34: 224-228. (Pubitemid 28267175)
89. Yom SS, Machtay M, Biel MA, et al. Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx. Am J Clin Oncol 2005; 28: 385-392. (Pubitemid 41099544)
90. Andry G, Hamoir M, Leemans CR,. The evolving role of surgery in the management of head and neck tumors. Curr Opin Oncol 2005; 17: 241-248. (Pubitemid 40586164)
91. Ferlito A, Corry J, Silver CE, Shaha AR, Robbins KT, Rinaldo A,. Planned neck dissection for patients with complete response to chemoradiotherapy: a concept approaching obsolescence. Head Neck 2010; 32: 253-261.
92. Clark JR, de Almeida J, Gilbert R, et al. Primary and salvage (hypo)pharyngectomy: analysis and outcome. Head Neck 2006; 28: 671-677. (Pubitemid 44116891)
93. Relic A, Scheich M, Stapf J, et al. Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas. Eur Arch Otorhinolaryngol 2009; 266: 1799-1805.
94. Tsou YA, Hua CH, Lin MH, Tseng HC, Tsai MH, Shaha A,. Comparison of pharyngocutaneous fistula between patients followed by primary laryngopharyngectomy and salvage laryngopharyngectomy for advanced hypopharyngeal cancer. Head Neck 2010 Feb 24. [Epub ahead of print]
95. Varghese BT, Sebastian P, Mathew A,. Treatment outcome in patients undergoing surgery for carcinoma larynx and hypopharynx: a follow-up study. Acta Otolaryngol 2009; 129: 1480-1485.
96. Dirven R, Swinson BD, Gao K, Clark JR,. The assessment of pharyngocutaneous fistula rate in patients treated primarily with definitive radiotherapy followed by salvage surgery of the larynx and hypopharynx. Laryngoscope 2009; 119: 1691-1695.
97. Homma A, Sakashita T, Oridate N, et al. Importance of comorbidity in hypopharyngeal cancer. Head Neck 2010; 32: 148-153.
98. Gourin CG, Johnson JT,. A contemporary review of indications for primary surgical care of patients with squamous cell carcinoma of the head and neck. Laryngoscope 2009; 119: 2124-2134.
99. Wong RJ, Shah JP,. The role of the head and neck surgeon in contemporary multidisciplinary treatment programs for advanced head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2010; 18: 79-82.
100. Chen SW, Yang SN, Liang JA, Lin FJ, Tsai MH,. Prognostic impact of tumor volume in patients with stage III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy. Head Neck 2009; 31: 709 - 716.
101. Takes RP, Rinaldo A, Silver CE, et al. Future of the TNM classification and staging system in head and neck cancer. Head Neck 2010 Feb 26. [Epub ahead of print]